Prostacyclin in experimental septic acute respiratory failure.
Manipulation of prostaglandins (PG) in animal models of sepsis and acute respiratory failure (ARF) is promising. Prostacyclin (PGI2), a short-acting vasodilator, was evaluated in a porcine model of ARF produced by continuous infusion of live Pseudomonas aeruginosa (Ps.). Cardiopulmonary parameters were monitored in three groups of spontaneously breathing animals that received 0.1 micrograms PGI2/kg/min begun 20 min after baseline (Group I); 2 X 10(8) Ps./20 kg/min (Group II); identical Ps. infusion and then PGI2 begun at 20 min (Group III). The decrease in mean arterial blood pressure and cardiac index with Ps. infusion was improved by PGI2 treatment. In Groups II and III, mean pulmonary artery pressure (PAP) doubled (P less than 0.005) and pulmonary vascular resistance (PVR) tripled (P less than 0.01) by 15 min. Both PAP and PVR were decreased significantly with PGI2 treatment. In both Ps. groups, significant hypoxemia occurred. PGI2 improves cardiac output and acts as a pulmonary vasodilator, but does not improve oxygenation in this porcine model of severe ARF.
D000208:Acute Disease; D000818:Animals; D011464:Epoprostenol / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects; D011453:Prostaglandins / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000150:complications; D011652:Pulmonary Circulation / Q000187:drug effects; D012131:Respiratory Insufficiency / Q000150:complications / Q000188:drug therapy*; D018805:Sepsis / Q000150:complications*; D013552:Swine
D011453:Prostaglandins; D011464:Epoprostenol